Company: CPMV
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001683168-25-002584
Chunk: 506

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 4
Chunk 506
---
 referred to as “Target
Common Stock”). In exchange for the Target Common Stock, the holders of the Class A Stock received 630,000 shares of the Company’s
Series A Convertible Voting Preferred Stock (“Series A Preferred”) and holders of the Class B Stock received 70,000 shares
of the Company’s Series B Convertible Voting Preferred Stock (“Series B Preferred”). Each share of Series A Preferred
converted into 10.194106 shares of common stock as defined in the Series A Certificate of Designation. Each share of Series B Preferred
converts into 11.46837 shares of common stock of the Company, possesses full voting rights, on an as-converted basis, as the common stock
of the Company and contains certain anti-dilution rights, as defined in the Series B Certificate of Designation. On a fully diluted, as
converted basis, the holders of Series A Preferred and Series B Preferred, in aggregate, owned 90% of the issued and outstanding common
stock of the Company as of the Closing Date.

The Reverse Merger was treated by the Company as a
reverse merger in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).
For accounting purposes, Private Mosaic was considered to have acquired PTSC as the accounting acquirer because: (i) Private Mosaic
stockholders owned 90% of the combined company, on an as-converted basis, immediately following the Closing Date, (ii) Private Mosaic
directors held a majority of board seats in the combined company and (iii) Private Mosaic management held all key positions in the
management of the combined company. Accordingly, Private Mosaic’s historical results of operations replaced PTSC’s historical
results of operations for all periods prior to the Closing Date of the Reverse Merger and, for all periods following the Closing Date
of the Reverse Merger, the results of operations of the combined company are included in the Company’s financial statements.

Other Key Corporate Events

On November 30, 2020, we filed amended and restated
articles of incorporation with the Secretary of State of the State of Delaware (“Amended and Restated Certificate”) to change
the name of the Company to Mosaic ImmunoEngineering, Inc. (“Name Change”) to align the Company’s corporate name with
its new strategic direction, to implement a 1-for-500 reverse stock split (“Reverse Stock Split”), and to reduce the number
of authorized shares of